

# UCLA

## UCLA Previously Published Works

### Title

The Genetics of Retinopathy of Prematurity: A Model for Neovascular Retinal Disease

### Permalink

<https://escholarship.org/uc/item/23b195cf>

### Journal

Ophthalmology Retina, 2(9)

### ISSN

2468-6530

### Authors

Swan, Ryan

Kim, Sang Jin

Campbell, J Peter

et al.

### Publication Date

2018-09-01

### DOI

10.1016/j.oret.2018.01.016

Peer reviewed



Published in final edited form as:

*Ophthalmol Retina*. 2018 September ; 2(9): 949–962. doi:10.1016/j.oret.2018.01.016.

## The genetics of retinopathy of prematurity: a model for neovascular retinal disease

Ryan Swan, BS<sup>1</sup>, Sang Jin Kim, MD, PhD<sup>2,3</sup>, J. Peter Campbell, MD, MPH<sup>2</sup>, R. V. Paul Chan, MD<sup>4,5</sup>, Kemal Sonmez, PhD<sup>6</sup>, Kent D. Taylor, PhD<sup>7</sup>, Xiaohui Li, MD<sup>7</sup>, Yii-Der Ida Chen, PhD<sup>7</sup>, Jerome I. Rotter, MD<sup>7</sup>, Charles Simmons, MD<sup>8</sup>, Michael F. Chiang, MD<sup>1,2</sup>, and the Imaging and Informatics in ROP Research Consortium

<sup>1</sup>Department of Medical Informatics & Clinical Epidemiology, Oregon Health & Science University, Portland, OR

<sup>2</sup>Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, OR

<sup>3</sup>Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

<sup>4</sup>Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, IL

<sup>5</sup>Center for Global Health, College of Medicine, University of Illinois at Chicago, Chicago, IL

<sup>6</sup>Center for Spoken Language Understanding, Oregon Health & Science University, Portland, OR

<sup>7</sup>Institute for Translational Genomics and Population Sciences and Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA

<sup>8</sup>Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA

### Abstract

**TOPIC**—Retinopathy of prematurity (ROP) is a proliferative retinal vascular disease in premature infants, and is a major cause of childhood blindness worldwide. In addition to known clinical risk factors such as low birth weight and gestational age, there is a growing body of evidence supporting a genetic basis for ROP.

**CLINICAL RELEVANCE**—While comorbidities and environmental factors have been identified as contributing to ROP outcomes in premature infants, most notably gestational age and oxygen,

---

Correspondence to: Michael F. Chiang, MD, Knowles Professor of Ophthalmology & Medical Informatics and Clinical Epidemiology, Casey Eye Institute at Oregon Health & Science University, 3375 SW Terwilliger Boulevard, Portland, OR 97239 | Tel: 503-494-7830 | [chiangm@ohsu.edu](mailto:chiangm@ohsu.edu).

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

No authors have financial conflicts of interest. Michael F. Chiang is an unpaid member of the Scientific Advisory Board for Clarity Medical Systems (Pleasanton, CA), and a Consultant for Novartis (Basel, Switzerland). R.V. Paul Chan is a member of the scientific advisory board for Visunex Medical Systems (Fremont, CA) and a consultant for Alcon (Fort Worth, TX), Allergan (Irvine, CA), and Bausch and Lomb (St. Louis, MO).

some infants progress to severe disease despite absence of these clinical risk factors. The contribution of genetic factors may explain these differences and allow better detection and treatment of infants at risk for severe ROP.

**METHODS**—To comprehensively review genetic factors that potentially contribute to the development and severity of ROP, we conducted a literature search focusing on the genetic basis for ROP. Terms related to other heritable retinal vascular diseases like “familial exudative vitreoretinopathy”, as well as to genes implicated in animal models of ROP, were also used to capture research in diseases with similar pathogenesis to ROP in humans with known genetic components.

**RESULTS**—Contributions across several genetic domains are described including vascular endothelial growth factor, the Wnt signaling pathway, insulin-like growth factor 1, inflammatory mediators, and brain-derived neurotrophic factor.

**CONCLUSIONS**—Most candidate gene studies of ROP have limitations such as inability to replicate results, conflicting results from various studies, small sample size, and differences in clinical characterization. Additional difficulty arises in separating the contribution of genetic factors like Wnt signaling to ROP and prematurity. Although studies have implicated involvement of multiple signaling pathways in ROP, the genetics of ROP have not been clearly elucidated. Next-generation sequencing and genome-wide association studies have potential to expand future understanding of underlying genetic risk factors and pathophysiology of ROP.

## INTRODUCTION

Retinopathy of prematurity (ROP) is a retinal vascular disorder affecting premature low birth weight infants, and is a major cause of childhood blindness in the United States and internationally. Beyond the clinical impact, infancy-acquired visual loss from ROP represents an enormous social and economic burden.<sup>1–4</sup> Furthermore, as the incidence of premature births worldwide increases and as medical technology becomes better able to treat the complications of premature birth, the number of infants at risk for ROP is increasing rapidly.<sup>5–8</sup>

Oxygen plays a central role in ROP.<sup>9–13</sup> Oxygen environment and a key transcription factor that oxygen regulates (e.g. Hypoxia inducible factor [HIF]) are thought to modulate ROP. In terms of ROP pathogenesis, a two-phase hypothesis has been proposed and has become widely accepted.<sup>14,15</sup> In phase 1, there is delayed physiologic retinal vascular development and vasoattenuation, which is aggravated by hyperoxia and loss of nutrients and growth factors. In phase 2, vasoproliferation occurs at the junction of vascularized and avascular retina. Mouse oxygen-induced retinopathy (OIR) model (exposure to 75% oxygen for 5 days followed by room air), a widely used animal model of ROP, best represents the two-phase hypothesis.<sup>16,17</sup> During the vasoproliferative phase, the avascular retina releases pro-angiogenic growth factors such as vascular endothelial growth factor (VEGF), which are induced by hypoxia and may cause aberrant vessel growth and neovascularization. Oxygen fluctuations with intermittent hypoxia is also implicated in development of ROP in clinical studies<sup>18–20</sup> and OIR animal model studies especially in rats (e.g. cycling between 50 and 10% oxygen).<sup>21,22</sup> Growing neovascular vessels lead to fibrovascular membranes that may

pull on the retina, causing tractional retinal detachment and eventual blindness. The phenotype of ROP is classified based on location, extent, and severity of these pathologic changes.<sup>23</sup> Some infants show a rapidly progressing, severe form of ROP, known as aggressive posterior ROP (AP-ROP).<sup>23–27</sup>

Early investigations into ROP risk factors focused primarily on prematurity itself, as well as environmental factors including oxygen exposure after birth.<sup>10,11</sup> Various studies focusing on oxygen exposure have proven its importance as a primary predictor of ROP outcomes.<sup>9–11</sup> However, some high-risk infants with extremely low birth weight (BW) and gestational age (GA) do not develop ROP, whereas some low-risk infants do develop severe ROP. In these infants at phenotypic extremes, a study showed that known clinical risk factors were not significantly associated with development of ROP.<sup>28</sup> In addition, it is not understood why certain infants are predisposed to AP-ROP with very high likelihood of blindness. This heterogeneity of ROP risk suggests that other factors, such as genetics may be involved in creating a predisposition to ROP. Before specific genetic variations were investigated in ROP, epidemiologic studies suggested racial and ethnic differences in ROP incidence.<sup>29–31</sup> The Cryotherapy for ROP (CRYO-ROP) study of 4,099 premature infants found 7.4% of white infants reached threshold disease, while only 3.2% of black infants achieved a similar level of disease.<sup>31</sup> Also, twin and sibling studies have supported the involvement of a genetic component of disease. Two studies of monozygotic and dizygotic twins found that the heritability of ROP was 0.70 and 0.73, respectively.<sup>32,33</sup> Evidence of genetic effects is also supported by data from the oxygen-induced retinopathy (OIR) phenotype in rodent models, in which studies of different rat strains have found differences in the retinal avascular area and VEGF expression between strains.<sup>34–36</sup> Investigations into this genetic component in humans and animal models have implicated the involvement of multiple genes, but have not discovered a genetic component of large effect. It is likely that knowledge of such a genetic component could be used to identify possible targets to improve outcomes of screening and treatment.

Many signaling molecules and related pathways have been suspected in the pathogenesis of ROP due to known biochemical and clinical associations: VEGF, insulin-like growth factor-1 (IGF-1), erythropoietin (EPO), and inflammatory mediators. In addition to ROP, the growth of abnormal, leaky blood vessels is a common pathologic component of other blinding neovascular eye diseases, such as diabetic retinopathy (DR) and neovascular age-related macular degeneration (AMD), both of which have strong evidence of a genetic predisposition to disease.<sup>37–39</sup> Moreover, because ROP progresses more rapidly and presents with relatively homogeneous clinical characteristics, the correlation of genotype and phenotype is easier than with a chronic disease such as DR or AMD.<sup>15</sup> Thus, the study of ROP genetics may give us important insights into the pathophysiology of other more prevalent adult and pediatric neovascular retinal diseases.

This review summarizes current research into genetic factors contributing to ROP risk in both human and animal models and recommends future directions for research into the underlying genetics of pathways that contribute to disease.

## METHODS

Pubmed was queried from January 1980 to June 2017. The following search terms were used: retinopathy of prematurity AND genetics, retinopathy of prematurity AND gene, retinopathy of prematurity AND single nucleotide polymorphism (SNP), retinopathy of prematurity AND variant, and retinopathy of prematurity AND polymorphism. Criteria for inclusion included the relevance, clinical importance, level of statistical evidence provided, and scientific importance of articles to the subject of this paper. Articles cited in the reference lists of other articles were reviewed and included when considered appropriate. All articles with English abstracts were reviewed.

## CANDIDATE GENES IN ROP

### VEGF and associated receptors

VEGF plays a crucial role in ROP. Increased VEGF in avascular retina stimulates pathological retinal neovascularization, which may result in blinding complications like tractional retinal detachment. Moreover, VEGF is a proven therapeutic target, as intravitreal anti-VEGF therapy has shown efficacy in promoting regression of severe ROP.<sup>40</sup> There have been many genetic studies on associations between the VEGF gene and incidence or severity of ROP.

Table 1 summarizes results of SNP studies in human VEGF gene (*VEGFA*). rs2010963 (also known as -634G>C and +405 G>C) is the most extensively studied SNP. In a British study of 188 preterm infants on rs2010963 in 2004, the G allele was found to have higher frequency among infants with ROP.<sup>41</sup> This result was supported by a 2015 study in 102 preterm infants from Egyptian hospitals showing that G allele was significantly higher in infants with ROP.<sup>42</sup> However, one study in Hungary reported the opposite results – higher frequency of C allele in severe ROP – and 5 other studies found no significant association between rs2010963 and ROP.

In addition, rs833061 (-460C>T) and *VEGFA* +13553C>T have been reported to be associated with ROP. However, replication has not been attempted for +13553C>T and the association of rs833061 and ROP has not been replicated in 3 other studies. *VEGFA* haplotypes have also been reported to be associated with ROP. A study performed in an Italian population of 342 infants focused on the distribution of polymorphisms in a handful of genes implicated in ROP showed evidence that *VEGFA* haplotype (TCCT) decreases risk of ROP.<sup>43</sup>

VEGF promotes angiogenesis and hyper-permeability by binding to the VEGF receptor 2 (VEGFR-2) on vascular endothelium, whereas VEGFR-1 acts as a decoy receptor.<sup>44</sup> However, studies on VEGFR-1 (*FLT1*) and -2 (*KDR*) genes found no associations with ROP (Table 2).

### FEVR, Norrie disease and the Wnt pathway

Familial Exudative Vitreoretinopathy (FEVR) and Norrie disease are developmental diseases of the retina with known genetic causes with similar pathology to ROP. Both are hereditary

disorders occurring primarily in full-term infants, characterized by abnormal retinal vascularization leading to retinal detachment.<sup>45,46</sup> While patients with Norrie disease are blind from or shortly after birth, and often have systemic pathologies such as deafness and mental retardation, the clinical manifestations of FEVR are variable but restricted to abnormalities in ocular development.<sup>47</sup> FEVR is known to be caused by mutations in *FZD4*, *LRP5*, *TSPAN12*, *NDP*, etc.,<sup>48–51</sup> and Norrie disease is caused by mutations in the *NDP* gene.<sup>46</sup> These genes encode proteins which are components of the Wnt/beta-catenin signaling pathway – a group of signal transduction pathways with roles in cell survival, proliferation, and migration throughout the body.

The canonical (beta-catenin dependent) Wnt pathway has known roles in a variety of diseases with angiogenic properties including DR and AMD.<sup>52,53</sup> Frizzled-4 and low-density-lipoprotein receptor related protein 5 (LRP-5) are receptors for Wnt ligands, and tetraspanin-12 is an auxiliary membrane protein. Norrin, a product of *NDP* gene, binds to the Frizzled-4, LRP-5, and tetraspanin-12 receptor complex and activates signals on endothelial cells. Mutations of these genes have been investigated in ROP (Table 2).

Mutations in the *FZD4* gene were found in up to 7.5% of patients with severe ROP (Table 2).<sup>54–57</sup> A 2015 study of 421 patients displaying various vitreoretinopathies found a significant association between the *FZD4* double missense mutation [P33S(;)P168S] and both ROP and FEVR.<sup>57</sup> A study of 53 Japanese patients with advanced ROP was performed using direct sequencing of *FZD4*, *TSPAN12*, *NDP*, and *LRP5*. Investigators identified six nonsynonymous DNA variants in the coding regions of *FZD4* and *LRP5*, but detected no changes in *NDP* or *TSPAN12*, demonstrating involvement of Wnt with ROP.<sup>56</sup>

Mutations in the *NDP* gene have also been found in ROP patients with variable frequencies (Table 2).<sup>58–60</sup> SNP studies in Kuwaiti populations have supported evidence of a link between *NDP* and ROP,<sup>60</sup> while other studies have implied that mutations in the regulatory region of *NDP* are also a contributor to the development of ROP.<sup>61</sup> The relationship between SNPs residing in the UTR of *NDP* and progression of ROP to advanced disease has also been investigated. The Kuwaiti study by Haider found that 83% of patients with severe disease possessed *NDP*597C>A polymorphisms in their UTR, while none of those whose disease resolved spontaneously possessed this polymorphism.<sup>60</sup>

Taken together, these findings intriguingly suggest involvement for the Wnt pathway and associated genes in ROP development, and serve as strong candidates for further sequencing research. It should be noted that it may be difficult or nearly impossible to differentiate ROP from FEVR in premature infants. This has recently been proposed as a new classification, ROPER (ROP vs. FEVR) due to the clinical similarity of the two conditions.<sup>62</sup> In future studies, in-depth analysis of clinical features, retinal imaging with fluorescein angiography, genetic and phenotypic analysis of relatives, and functional analysis of genetic variants may be helpful for better understanding of genetics in ROP as well as FEVR.

## IGF-1

Insulin-like growth factor 1 (IGF-1), a growth hormone promoting somatic growth and maturation, has also been proposed as a contributing factor to ROP progression.<sup>63</sup> IGF-1-

deficient mice showed a decrease in vascular development<sup>61</sup> and lower birth weight<sup>64</sup> than those of controls. In human babies, low IGF-1 levels were also associated with low birth weight,<sup>65</sup> and persistent low serum IGF-1 levels were associated with severity of ROP.<sup>63,66</sup> Based on these findings, IGF-1 replacement therapy has recently been investigated.<sup>67</sup> A phase 2 trial of administering a complex of recombinant human IGF-1 and IGFBP-3 to prevent ROP was undertaken, but the study did not meet its primary endpoint of reducing severity of ROP.<sup>68</sup>

Investigations of specific polymorphisms of *IGF-1* gene have been unsuccessful finding a significant association. A study linked a c.3174G>A polymorphism in the IGF-1 receptor gene (*IGF1R*) to low levels of plasma IGF-1.<sup>69</sup> A 2006 study of 392 infants in Hungary was unable to detect a difference in the prevalence of the *IGF1R* c.3174G>A among severe ROP, mild ROP and full-term groups (Table 2).<sup>70</sup> A 2007 study in an American population was also unable to find a link between advanced ROP and *IGF1R* c.3174G>A polymorphism (Table 2).<sup>71</sup>

### eNOS

Endothelial nitric oxide synthase (eNOS) is one of the constitutive enzymes that synthesize NO, which is known to play a regulatory role in retinal and choroidal blood flow.<sup>72,73</sup> In an eNOS-deficient mouse OIR model, neovascularization and vaso-obliteration were both reduced.<sup>74</sup> Moreover, eNOS gene polymorphisms have shown reduced NO levels.<sup>75</sup> Thus, the association between ROP and eNOS gene (*NOS3*) polymorphisms have been investigated. A literature search showed that 3 SNPs (rs2070744, rs1799983 and rs61722009) and one variable number tandem repeat (VNTR), 27-bp VNTR in intron 4, had been observed in ROP patients (Table 2). Although some studies reported positive associations between rs2070744, rs1799983, or the 27-bp VNTR and ROP, others found contradictory results (Table 2).

### Inflammatory Mediators

Growing evidence suggests that perinatal inflammation and infection may increase the risk for ROP by direct proangiogenic effects and/or modifying known risk factors.<sup>76</sup> Studies have reported higher plasma levels of inflammatory cytokines including IL-6, IL-8, and TNF<sup>77</sup> and higher vitreous levels of inflammatory cytokines including IL-6, IL-7, IL-10, IL-15, etc. in eyes with advanced ROP.<sup>78</sup>

Dammann et al investigated 4 SNPs of inflammation-associated genes (IL1B, TNF, IL10, TLR4) in preterm patients, but none showed significant association, although there were trends towards higher stage of ROP with the presence of *TNF* and *IL1B* SNPs (Table 2).<sup>76</sup> *TNF*-308G>A polymorphism also showed no significant associations with ROP (Table 2).

A recent study has also shown an angiogenic role for mast cells and associated factors including mast cell tryptase and monocyte chemoattractant protein-1, making them a potential target for ROP research.<sup>79</sup>



### Brain-derived neurotrophic factor

Brain-derived neurotrophic factor (BDNF), a neuronal trophic factor in brain and retina, may promote survival of several types of retinal neurons.<sup>80–83</sup> Although the exact role of BDNF in retinal angiogenesis is unknown, reduced BDNF levels have been demonstrated in patients with severe ROP, suggesting a possible role of BDNF in development of severe ROP.<sup>84–86</sup> In an animal model study, the retinal level of BDNF was lower in the OIR mouse model compared to that in normal controls.<sup>86</sup>

In a large-scale candidate gene study, which analyzed 1614 Tag SNPs of the 145 candidate genes in 817 infants in the discovery cohort and 543 in the US replication cohort, it was found that two SNPs (rs7934165 and rs2049046) in the intronic region of *BDNF* were associated with severe ROP. Although these results were not independently confirmed in the replication cohort, the association with rs7934165 did increase in significance with severe ROP in their meta-analysis of the combined data. Interestingly, reduced serum BDNF in the severe ROP group was also found in the same discovery cohort.<sup>87</sup> Further studies on the functional effects of intronic variants of *BDNF* and replication studies in different populations are warranted.

### Renin-Angiotensin System

The Renin Angiotensin system (RAS) has been linked to retinal vascular development and pathological angiogenesis. Blockade of RAS with inhibitors of angiotensin-converting enzyme (ACE) and angiotensin receptor blockers ameliorated OIR, suggesting that inhibiting RAS may be beneficial in ROP.<sup>88</sup> A SNP study of *ACE* gene showed association with DR.<sup>87</sup>

However, results from genetic studies on RAS component genes in ROP are inconclusive (Table 2). A study in Italy showed no associations between ROP and SNPs of *ACE* gene (*ACE*), angiotensinogen gene (*AGT*) and angiotensinogen type 1 receptor gene (*AGTR1*). In a study of 181 premature Kuwaiti infants on 287-bp insertion(I)/deletion(D) in intron 16, the frequency of II genotype was higher in ROP patients compared to normal controls, but the frequency of DD genotype was higher in advanced ROP patients compared to regressed ROP.<sup>90</sup> A candidate gene study of 228 infants with ROP and 102 controls found a SNP in the *AGTR1* gene to be associated with ROP, though this association was not significant after Bonferroni correction.<sup>91</sup>

### Angiopoietins

Angiopoietin(Ang)-1 and -2 are growth factors that are essential for retinal vascular development. Ang-1 binds tyrosine kinase receptor Tie2 and promotes vascular maturation and stabilization.<sup>92</sup> In an OIR model, intravitreal Ang-1 promoted normal vascular regeneration while inhibiting pathological angiogenesis and vascular leakage.<sup>93</sup> In contrast, Ang-2, a competitive antagonist of Ang-1/Tie-2, promotes neovascularization in animal models.<sup>94,95</sup> Vitreous levels of Ang-1 and Ang-2 in eyes of stage 4 ROP were higher than those of control eyes.<sup>96</sup> However, in two studies of Ang-2 gene promoter polymorphism (*ANGPT2* –35G>C), no association was found with ROP (Table 2).



## Erythropoietin

Erythropoietin (EPO), a hormone known to stimulate red blood cell formation in bone marrow, and EPO receptors are expressed in retina, and their expression is regulated by oxygen status.<sup>97,98</sup> Mouse models of ROP have shown that vascular stability is affected by EPO levels, with exogenous restoration of EPO leading to a reduction in blood vessel dropout during the first phase of ROP.<sup>96</sup> Conversely, elevated levels of EPO during the second stage of ROP exacerbated vasoproliferation, and the vitreous level of EPO is elevated in eyes with stage 4 ROP. Increased erythropoietin receptor signaling has also been shown to influence severe OIR models of disease through VEGFR2-mediated angiogenesis, making it an important target for clinical research in human patients.<sup>99,100</sup> While a variant of EPO was investigated in a candidate-gene study by Mohamed et. al., significance for this variant was not reported in the study results.<sup>91</sup>

## Hypoxia inducible factor

HIF-1 plays a central role in oxygen homeostasis.<sup>101</sup> According to the oxygen environment, HIF-1 regulates transcription of genes such as VEGF, VEGFR1, PDGF, SDF-1 and Ang2, which have been suggested to play important roles in retinal angiogenesis.<sup>94</sup> In a study of Hif1 $\alpha$  knockout mice in an OIR model of disease, disruption of HIF-1 was shown to lead to decreased VEGF abundance, indicating a possible role in neovascularization.<sup>102</sup> Additionally, organ system pharmacology studies in mouse models have indicated that stabilization of HIF-1 may be important for protection against oxygen toxicity in premature infants.<sup>103</sup>

Likewise, homologous recombination models in mice studying HIF-1 $\alpha$ -like factor (HLG) and HIF2 $\alpha$  found decreasing expression of these genes led to decreased EPO expression and resistance to hyperoxia treatments meant to induce ROP.<sup>104</sup> HIF1 $\alpha$  was also shown to upregulate annexin A2 expression in OIR mice during hypoxia, supporting a role in OIR models.<sup>105</sup>

HIF2 $\alpha$ 's closest human analogue, known as Endothelial PAS Domain Protein 1 (EPAS1), serves as the main regulator of EPO induction and has also been shown to have a connection to ROP.<sup>106</sup> A candidate gene study of 153 genes in 347 infants under 32 weeks gestational age found an association between EPAS1 with development of severe ROP.<sup>91</sup>

## Heme oxygenase-1

Heme oxygenase-1 plays important roles in inflammatory responses, oxidative stress, iron-metabolism, and vascular physiology. However, in a candidate gene study, rs3074372 in *HMOX1* showed no significant association with ROP (Table 2).

**Other candidate factors**—In addition to the above described factors and pathways, a number of other potential targets and mechanisms have been identified that lack genetic studies in patients with ROP. The 'a' disintegrin and metalloproteinase (ADAM) family of proteases are involved in the degradation of extracellular matrix components as well as interactions mediated by integrin.<sup>107</sup> Several subtypes of ADAM family are implicated in the pathogenesis of ROP. ADAM17 knockout mice showed less neovascularization in OIR

models without affecting normal vascular development.<sup>108</sup> Moreover, ADAM 8, 9, and 10 was found to play a role in development of plus disease in OIR mouse models. Adam8<sup>-/-</sup> and Adam9<sup>-/-</sup> mice and mice lacking ADAM10 in endothelial cells showed less severe tortuosity and dilation mimicking less plus disease in ROP.<sup>109</sup> Further evaluations in humans including genetic analysis are warranted.

In conjunction with ADAM17, studies have also considered the family of tissue inhibitor of metalloproteinases (TIMP) family of proteins. The TIMP-3 protein specifically is a known physiological ADAM17 inhibitor.<sup>110</sup> Mouse model investigations into the application of this protein as a potential treatment showed that TIMP-3 application was linked to decreased neovascular tuft formation.<sup>109</sup>

In addition to these studies, large candidate gene studies of ROP have been successful identifying targets with undiscovered connections to ROP. The previously mentioned study by Mohamed et al. implicated genes with function in embryonic development (*IHH*), transcription (*TBX5*), and protein localization (*GP1BA*, *CETP*) (Table 2).<sup>91</sup> The same study also found an association between ROP and complement factor H (*CFH*), known to be associated with development of AMD.<sup>38</sup>

## DISCUSSION

### Summary of previous studies

Most genetic studies in ROP have used the candidate gene approach and focused on genes related to angiogenesis, inflammation, and retinal (neuro)development. Among them, *VEGFA* polymorphisms and FEVR-related genes have been most extensively studied in different populations. However, no *VEGFA* polymorphisms have been proven to be associated with ROP, because most positive studies have not been replicated in other populations (Table 1). Variants of Wnt pathway genes, which are known to cause FEVR or Norrie disease, have been also found in ROP patients, suggesting possible associations of these variants in at least a small proportion of severe ROP patients (Table 2). However, these results also have limitations in that we may not confidently distinguish between premature infants with severe ROP and FEVR-related genetic variants and prematurely-born infants with FEVR, as Hartnett et al. pointed out.<sup>27</sup> In addition the polygenic nature of many diseases makes identification of causative variants difficult in small sample sizes focused on a small number of variants.<sup>111</sup> Recently, results of a large-scale candidate gene study using Tag SNPs of the 145 candidate genes in a multiracial cohort were reported.<sup>87</sup> Although no SNPs were significantly associated with the presence versus absence of ROP in this study, one SNP of *BDNF* gene was significantly associated with severe ROP in their meta-analysis combining the discovery and replication cohorts, which warrants further genetic and biological studies.

### Limitations of previous studies

It is difficult to draw meaningful conclusions from most of the candidate gene studies reviewed here due to the following limitations: (1) the sample sizes of most individual studies were small; (2) no replication study has been performed for many variants; (3) there

are conflicting results among studies of the same variants; (4) most studies were conducted using only one or a few clinical sites; (5) ocular phenotype was not standardized; (6) confounding variables were not reported or standardized; (7) meta-analysis is not possible for most variants due to different study protocols between studies; (8) there are variabilities in neonatal care such as oxygen treatment protocol<sup>9</sup>, incidence of (severe) ROP, and diagnosis and management of ROP between physicians, study hospitals, study countries and study periods.<sup>8,112–115</sup> Differences in neonatal care may affect survival rate, systemic morbidities of prematurity, incidence of ROP and severity of ROP, making it difficult to find exact roles of genetic variants. Moreover, there are unexplained differences in outcome of premature birth such as mortality. Also, differences in diagnosis and management of ROP may cause bias in phenotypic categorization of subjects, which is a huge problem in genetic studies. It should be noted that genetic risk factors for stage 1-3 ROP and stage 4 or 5 ROP could be different, as different biochemical processes may be involved and management protocols and treatment outcomes of study centers are also important factors for stage 4 or 5 ROP.

Most importantly, candidate gene studies have inherent limitations of not being able to find novel genetic factors. Other approaches to detect novel variants or genes associated with ROP are necessary.

### Future Directions of studying ROP genetics

It is very challenging to study the genetics of multifactorial diseases such as ROP. To overcome the current limitations mentioned above and to study the contribution of genetics efficiently, it is necessary to improve the methodology for studying the genetics of ROP. It is essential that investigators leverage new methods that interrogate genetic factors agnostically and at high sample sizes, in order to maximize study power and facilitate simultaneous investigation of many, rather than single, genetic elements. Genome-wide Association Studies (GWAS) test for association across hundreds of thousands of SNPs simultaneously using array-based technology. GWAS can be helpful to find genes or pathways associated with ROP. In other ophthalmological diseases such as AMD<sup>38,116–118</sup>, DR<sup>119,120</sup>, glaucoma<sup>121–123</sup> and myopia<sup>124–126</sup>, GWAS has been successful in finding susceptibility loci. However, a large-scale GWAS has not been conducted in ROP. Massively parallel sequencing, also called next-generation sequencing (NGS), enables sequencing of specific regions, whole exome, or whole genome in a short period of time at high depth and affordable cost. Whole exome sequencing or targeted exome sequencing can be helpful for finding novel variants with possible functional consequences. Exome genotyping arrays may also provide a method of interrogating for SNPs involved in ROP.

In addition to these genetic evaluations, integration of sequence data with data regarding post-transcriptional and post-translational modification, including transcriptomics, metabolomics, and proteomics, will be important to identify biomarkers that may be useful for early detection, diagnosis, and prediction of treatment response. Studies of epigenetics in DR have also shown promise, with epigenetic changes associated with processes of microvasculature complications<sup>127</sup>, mitochondrial dysfunction<sup>128</sup>, microRNA expression<sup>129</sup>,

and capillary cell apoptosis.<sup>130,131</sup> These findings suggest that interrogation of epigenetic factors may be an important method of discovering new treatments in ROP.

Second, large-scale multi-center collaboration of the type offered by consortium studies can help provide structure to such studies. Consortium approaches facilitate recruitment of larger cohorts and make available more sophisticated computational approaches allowing investigators to control for more complicated confounding effects. Previous large international consortium attempts at examining the role of genetics in multifactorial disease have met with success<sup>38,121,132–134</sup>, and two consortium studies investigating the genetic causes of ROP are currently ongoing at centers in North America.<sup>135,136</sup>

Third, standardization of ocular phenotypes and confounding factors is crucial. For this, ocular and systemic factors should be acquired systematically, and known risk factors including GA and BW should be assessed in a standardized fashion and strictly controlled for. Additionally, the importance of environmental effects should be noted, as differences between study populations and sites has the ability to have a profound effect on phenotype. Heterogeneity of study subjects in race, ethnicity, and physical covariates, as well as differences between treatment sites and attending clinicians can affect study outcomes. This is especially important to distinguish genetic variants associated with ROP from those associated with prematurity itself. Also, objective phenotyping such as image-based diagnosis should be considered. Compared to clinical ophthalmoscopic diagnosis, consensus image-based diagnosis may enable reduction of intra- and inter-grader discrepancy in ROP diagnosis.

It is also important to note that additional basic research studies using representative animal models such as mouse or rat OIR models are required to test hypotheses. While animal models face many limitations including differences in biology, most notably their use of full-term rather than premature animals, these models' ability to control for phenotypic, environmental, and genetic stratification factors distinguishes them as a valuable method of testing hypotheses and adding insight to human observational studies.

### **Expected benefits of genetic studies of ROP**

Finding genetic variants affecting ROP will be useful in at least three ways. First, genetic risk factors may be incorporated into risk modelling to predict development and progression of ROP. A refined risk analysis system with clinical and genetic risk factors may help clinicians to identify both high- and low-risk patients. Second, identifying specific genes or biological pathways that contribute the pathogenesis of ROP may be helpful for development of new therapeutics. In AMD, genetic studies have revealed the importance of complement pathway in the pathogenesis of AMD, which has led to development of new investigational agents under clinical trials such as lampalizumab, an inhibitor of complement factor D. Third, studying ROP genetics can also contribute to the understanding of pathophysiologies of other ocular vascular diseases such as AMD or DR and other angiogenesis-related diseases like cancer.<sup>15</sup> Fourth, a better understanding of the genetics of retinopathy of prematurity may lead to better understanding of the pathophysiologic mechanisms of common neonatal diseases of prematurity such as chronic lung disease.

## Conclusion

Evidence suggests a genetic contribution to ROP, including epidemiologic studies, twin studies and risk analysis studies. To date, a number of candidate gene studies have been performed. However, it is still unclear which genes or variants are significantly and strongly associated with development and progression of ROP. Large-scale studies using NGS and GWAS with standardized phenotyping have potential to expand understanding of genetic contributions and pathophysiology of ROP.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

Supported by grants R01EY19474, P30EY10572, and T32EY023211 from the National Eye Institute (Bethesda, MD); by the National Center for Advancing Translational Sciences; by CTSI grant UL1TR001881; by the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491; by grant SCH-1622679 from the National Science Foundation (Arlington, VA); and by unrestricted departmental funding from Research to Prevent Blindness (New York, NY).

## ABBREVIATIONS

|                 |   |
|-----------------|---|
| <b>ROP</b>      | Retinopathy of Prematurity                      |
| <b>AP-ROP</b>   | aggressive posterior retinopathy of prematurity |
| <b>BW</b>       | birth weight                                    |
| <b>GA</b>       | gestational age                                 |
| <b>CRYO-ROP</b> | cryotherapy for ROP                             |
| <b>OIR</b>      | oxygen induced retinopathy                      |
| <b>DR</b>       | diabetic retinopathy                            |
| <b>AMD</b>      | age-related macular degeneration                |
| <b>FEVR</b>     | familial exudative vitreoretinopathy            |
| <b>UTR</b>      | untranslated region                             |

## References

1. Reese AB. Symposium: Retrolental fibroplasia (retinopathy of prematurity). *Am J Ophthalmol.* 1955; 40:159.
2. Reese A, King M, Owens W. A classification of retrolental fibroplasia. *Am J Ophthalmol.* 1953; 36:1333–1335. [PubMed: 13092190]
3. Tasman W. Vitreoretinal changes in cicatricial retrolental fibroplasia. *Trans Am Ophthalmol Soc.* 1970; 68:548. [PubMed: 5538153]
4. Aiken JW, Vane JR. Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin. *J Pharmacol Exp Ther.* 1973; 184:678–687. [PubMed: 4347050]

5. Tysinger JW, Weidenthal DT. Nasal heterotopia of the macula in retinopathy of prematurity. *Am J Ophthalmol.* 1977; 83:499–500. [PubMed: 577378]
6. Tasman W. Retinal detachment in retrolental fibroplasia. *Albrecht Von Graefes Arch Klin Exp Ophthalmol.* 1975; 195:129–139. [PubMed: 1079704]
7. Harris G. Retinopathy of prematurity and retinal detachment. *Canadian journal of ophthalmology Journal canadien d'ophthalmologie.* 1976; 11:21–25.
8. Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. *Early Hum Dev.* 2008; 84:77–82. [PubMed: 18234457]
9. Saugstad OD, Aune D. Optimal oxygenation of extremely low birth weight infants: a meta-analysis and systematic review of the oxygen saturation target studies. *Neonatology.* 2014; 105:55–63. [PubMed: 24247112]
10. Kinsey VE, Jacobus JT, Hemphill F. Retrolental fibroplasia: cooperative study of retrolental fibroplasia and the use of oxygen. *AMA archives of ophthalmology.* 1956; 56:481–543. [PubMed: 13361620]
11. Flynn JT, Bancalari E, Snyder ES, et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. *N Engl J Med.* 1992; 326:1050–1054. [PubMed: 1549150]
12. Hartnett ME, Lane RH. Effects of oxygen on the development and severity of retinopathy of prematurity. *Journal of American Association for Pediatric Ophthalmology and Strabismus.* 2013; 17:229–234. [PubMed: 23791404]
13. Heidary G, Vanderveen D, Smith LE. Retinopathy of prematurity: current concepts in molecular pathogenesis. Paper presented at: *Semin Ophthalmol.* 2009
14. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. *N Engl J Med.* 2012; 367:2515–2526. [PubMed: 23268666]
15. Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. *Invest Ophthalmol Vis Sci.* 2008; 49:5177–5182. [PubMed: 18708611]
16. Smith L, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. *Invest Ophthalmol Vis Sci.* 1994; 35:101–111. [PubMed: 7507904]
17. Connor KM, Krahn NM, Dennison RJ, et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. *Nat Protoc.* 2009; 4:1565–1573. [PubMed: 19816419]
18. Cunningham S, McIntosh N, Fleck B, Elton R. Transcutaneous oxygen levels in retinopathy of prematurity. *The Lancet.* 1995; 346:1464–1465.
19. York JR, Landers S, Kirby RS, Arbogast PG, Penn JS. Arterial oxygen fluctuation and retinopathy of prematurity in very-low-birth-weight infants. *J Perinatol.* 2004; 24:82–87. [PubMed: 14762452]
20. Saito Y, Omoto T, Cho Y, Hatsukawa Y, Fujimura M, Takeuchi T. The progression of retinopathy of prematurity and fluctuation in blood gas tension. *Graefe's archive for clinical and experimental ophthalmology.* 1993; 231:151–156.
21. Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. *Pediatr Res.* 1994; 36:724–731. [PubMed: 7898981]
22. Penn JS, Henry MM, Wall P, Tolman BL. The range of PaO<sub>2</sub> variation determines the severity of oxygen-induced retinopathy in newborn rats. *Invest Ophthalmol Vis Sci.* 1995; 36:2063–2070. [PubMed: 7657545]
23. Gole GA, Ells AL, Katz X, et al. The international classification of retinopathy of prematurity revisited. *JAMA Ophthalmology.* 2005; 123:991–999.
24. Zacharias L. Retrolental fibroplasia: a survey. *Am J Ophthalmol.* 1952; 35:1426–1454. [PubMed: 12985789]
25. Schaffer DB, Palmer EA, Plotsky DF, et al. Prognostic factors in the natural course of retinopathy of prematurity. *Ophthalmology.* 1993; 100:230–237. [PubMed: 8437832]
26. Palmer EA. Results of US randomized clinical trial of cryotherapy for ROP (CRYO-ROP). *Doc Ophthalmol.* 1990; 74:245–251. [PubMed: 2209383]
27. Hartnett EM. Features associated with surgical outcome in patients with stages 4 and 5 retinopathy of prematurity. *Retina.* 2003; 23:322–329. [PubMed: 12824831]



28. Port AD, Chan RP, Ostmo S, Choi D, Chiang MF. Risk factors for retinopathy of prematurity: insights from outlier infants. *Graefe's Archive for Clinical and Experimental Ophthalmology*. 2014; 252:1669–1677.
29. Ng Y, Shaw D, Fielder A, Levene M. Epidemiology of retinopathy of prematurity. *The Lancet*. 1988; 332:1235–1238.
30. Tadesse M, Dhanireddy R, Mittal M, Higgins RD. Race, Candida sepsis, and retinopathy of prematurity. *Neonatology*. 2002; 81:86–90.
31. Saunders RA, Donahue ML, Christmann LM, et al. Racial variation in retinopathy of prematurity. *Arch Ophthalmol*. 1997; 115:604–608. [PubMed: 9152127]
32. Bizzarro MJ, Hussain N, Jonsson B, et al. Genetic susceptibility to retinopathy of prematurity. *Pediatrics*. 2006; 118:1858–1863. [PubMed: 17079555]
33. Ortega-Molina J, Anaya-Alaminos R, Uberos-Fernández J, et al. Genetic and environmental influences on retinopathy of prematurity. *Mediators Inflamm*. 2015; 2015
34. van Wijngaarden P, Coster DJ, Brereton HM, Gibbins IL, Williams KA. Strain-dependent differences in oxygen-induced retinopathy in the inbred rat. *Invest Ophthalmol Vis Sci*. 2005; 46:1445–1452. [PubMed: 15790914]
35. Floyd B, Leske DA, Wren S, Mookadam M, Fautsch MP, Holmes JM. Differences between rat strains in models of retinopathy of prematurity. *Mol Vis*. 2005; 11:524–530. [PubMed: 16052168]
36. van Wijngaarden P, Brereton HM, Coster DJ, Williams KA. Genetic influences on susceptibility to oxygen-induced retinopathy. *Invest Ophthalmol Vis Sci*. 2007; 48:1761–1766. [PubMed: 17389509]
37. Kuo JZ, Wong TY, Rotter JI. Challenges in elucidating the genetics of diabetic retinopathy. *JAMA ophthalmology*. 2014; 132:96–107. [PubMed: 24201651]
38. Fritsche LG, Igl W, Bailey JNC, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. *Nat Genet*. 2016; 48:134. [PubMed: 26691988]
39. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. *The Lancet*. 2012; 379:1728–1738.
40. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. *N Engl J Med*. 2011; 364:603–615. [PubMed: 21323540]
41. Cooke RW, Drury JA, Mountford R, Clark D. Genetic polymorphisms and retinopathy of prematurity. *Invest Ophthalmol Vis Sci*. 2004; 45:1712–1715. [PubMed: 15161830]
42. Ali AA, Hussien NF, Samy RM, Al Husseiny K. Polymorphisms of Vascular Endothelial Growth Factor and Retinopathy of Prematurity. *J Pediatr Ophthalmol Strabismus*. 2015; 52:245–253. [PubMed: 25992764]
43. Poggi C, Giusti B, Gozzini E, et al. Genetic Contributions to the Development of Complications in Preterm Newborns. *PLoS One*. 2015; 10:e0131741. [PubMed: 26172140]
44. Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. *Ophthalmology*. 2013; 120:106–114. [PubMed: 23031671]
45. Criswick V, Schepens C. Familial exudative vitreoretinopathy. *Am J Ophthalmol*. 1969; 68:578–594. [PubMed: 5394449]
46. Chen Z, Battinelli E, Fielder A, et al. A mutation in the norrie disease gene (ndp) associated with x-linked familial exudative vitreoretinopathy. *Nat Genet*. 1993; 5:180–183. [PubMed: 8252044]
47. Shastry B, Hiraoka M, Trese D, Trese M. Norrie disease and exudative vitreoretinopathy in families with affected female carriers. *Eur J Ophthalmol*. 1999; 9:238–242. [PubMed: 10544980]
48. Robitaille J, MacDonald ML, Kaykas A, et al. Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. *Nat Genet*. 2002; 32:326–330. [PubMed: 12172548]
49. Ye X, Wang Y, Cahill H, et al. Norrin, frizzled-4, and Lrp5 signaling in endothelial cells controls a genetic program for retinal vascularization. *Cell*. 2009; 139:285–298. [PubMed: 19837032]
50. Xia C-H, Liu H, Cheung D, et al. A model for familial exudative vitreoretinopathy caused by LPR5 mutations. *Hum Mol Genet*. 2008; 17:1605–1612. [PubMed: 18263894]



51. Poulter JA, Ali M, Gilmour DF, et al. Mutations in TSPAN12 cause autosomal-dominant familial exudative vitreoretinopathy. *The American Journal of Human Genetics*. 2010; 86:248–253. [PubMed: 20159112]
52. Kwan H, Pecenka V, Tsukamoto A, et al. Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice. *Mol Cell Biol*. 1992; 12:147–154. [PubMed: 1530875]
53. Jin T. The WNT signalling pathway and diabetes mellitus. *Diabetologia*. 2008; 51:1771–1780. [PubMed: 18696049]
54. MacDonald M, Goldberg Y, Macfarlane J, Samuels M, Trese M, Shastry B. Genetic variants of frizzled 4 gene in familial exudative vitreoretinopathy and advanced retinopathy of prematurity. *Clin Genet*. 2005; 67:363–366. [PubMed: 15733276]
55. Ells A, Guernsey DL, Wallace K, et al. Severe retinopathy of prematurity associated with FZD4 mutations. *Ophthalmic Genet*. 2010; 31:37–43. [PubMed: 20141357]
56. Kondo H, Kusaka S, Yoshinaga A, Uchio E, Tawara A, Tahira T. Genetic variants of FZD4 and LRP5 genes in patients with advanced retinopathy of prematurity. 2013
57. Dailey WA, Gryc W, Garg PG, Dresner KA. Frizzled-4 variations associated with retinopathy and intrauterine growth retardation: a potential marker for prematurity and retinopathy. *Ophthalmology*. 2015; 122:1917–1923. [PubMed: 26119001]
58. Shastry BS, Pendergast SD, Hartzler MK, Liu X, Trese MT. Identification of missense mutations in the Norrie disease gene associated with advanced retinopathy of prematurity. *Arch Ophthalmol*. 1997; 115:651–655. [PubMed: 9152134]
59. Hiraoka M, Berinstein DM, Trese MT, Shastry BS. Insertion and deletion mutations in the dinucleotide repeat region of the Norrie disease gene in patients with advanced retinopathy of prematurity. *J Hum Genet*. 2001; 46:178–181. [PubMed: 11322656]
60. Haider M, Devarajan L, Al-Essa M, Kumar H. A C597→A polymorphism in the Norrie disease gene is associated with advanced retinopathy of prematurity in premature Kuwaiti infants. *J Biomed Sci*. 2002; 9:365–370. [PubMed: 12145535]
61. Talks SJ, Ebenezer N, Hykin P, et al. De novo mutations in the 5e 5n the Norrie disease gene associated with advanced retinopathy of prematurity. *J Med Genet*. 2001; 38:e46–e46. [PubMed: 11748312]
62. John VJ, McClintic JI, Hess DJ, Berrocal AM. Retinopathy of prematurity versus familial exudative vitreoretinopathy: report on clinical and angiographic findings. *Ophthalmic Surgery, Lasers and Imaging Retina*. 2016; 47:14–19.
63. Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. *Proceedings of the National Academy of Sciences*. 2001; 98:5804–5808.
64. Powell-Braxton L, Hollingshead P, Warburton C, et al. IGF-I is required for normal embryonic growth in mice. *Genes Dev*. 1993; 7:2609–2617. [PubMed: 8276243]
65. Ashton I, Zapf J, Einschenk I, MacKenzie I. Insulin-like growth factors (IGF) 1 and 2 in human foetal plasma and relationship to gestational age and foetal size during midpregnancy. *Acta Endocrinol (Copenh)*. 1985; 110:558–563. [PubMed: 3911715]
66. Hellström A, Engström E, Hård A-L, et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. *Pediatrics*. 2003; 112:1016–1020. [PubMed: 14595040]
67. Hellstrom A, Ley D, Hallberg B, et al. IGF-1 as a drug for preterm infants: a step-wise clinical development. *Curr Pharm Des*. 2017
68. Shire. IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity. Available from: <https://clinicaltrials.gov/ct2/show/NCT01096784>. NLM identifier: NCT01096784. Accessed 10.10.2017
69. Bonafè M, Barbieri M, Marchegiani F, et al. Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: cues for an evolutionarily conserved mechanism of life span control. *The Journal of Clinical Endocrinology & Metabolism*. 2003; 88:3299–3304. [PubMed: 12843179]
70. Balogh Á, Derzbach L, Vannay Á, Vászrhelyi B. Lack of association between insulin-like growth factor I receptor G+ 3174A polymorphism and retinopathy of prematurity. *Graefe's Archive for Clinical and Experimental Ophthalmology*. 2006; 244:1035–1038.

71. Shastry B. Assessment of the contribution of insulin-like growth factor I receptor 3174 G→A polymorphism to the progression of advanced retinopathy of prematurity. *Eur J Ophthalmol.* 2007; 17:950–953. [PubMed: 18050122]
72. Schmetterer L, Polak K. Role of nitric oxide in the control of ocular blood flow. *Prog Retin Eye Res.* 2001; 20:823–847. [PubMed: 11587919]
73. Ando A, Yang A, Mori K, et al. Nitric oxide is proangiogenic in the retina and choroid. *J Cell Physiol.* 2002; 191:116–124. [PubMed: 11920687]
74. Brooks SE, Gu X, Samuel S, et al. Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice. *Invest Ophthalmol Vis Sci.* 2001; 42:222–228. [PubMed: 11133872]
75. Tsukada T, Yokoyama K, Arai T, et al. Evidence of association of the eNOS gene polymorphism with plasma NO metabolite levels in humans. *Biochem Biophys Res Commun.* 1998; 245:190–193. [PubMed: 9535806]
76. Dammann O, Brinkhaus M-J, Bartels DB, et al. Immaturity, perinatal inflammation, and retinopathy of prematurity: a multi-hit hypothesis. *Early Hum Dev.* 2009; 85:325–329. [PubMed: 19217727]
77. Silveira RC, Fortes Filho JB, Procianoy RS. Assessment of the contribution of cytokine plasma levels to detect retinopathy of prematurity in very low birth weight infants. *Invest Ophthalmol Vis Sci.* 2011; 52:1297–1301. [PubMed: 21071735]
78. Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. *Ophthalmology.* 2009; 116:1599–1603. [PubMed: 19371954]
79. Matsuda K, Okamoto N, Kondo M, et al. Mast cell hyperactivity underpins the development of oxygen-induced retinopathy. *The Journal of clinical investigation.* 2017; 127:3987–4000. [PubMed: 28990934]
80. Barde Y-A, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. *The EMBO journal.* 1982; 1:549. [PubMed: 7188352]
81. Hyman C, Hofer M, Barde Y-A, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. *Nature.* 1991; 350:230–232. [PubMed: 2005978]
82. Chen H, Weber AJ. BDNF enhances retinal ganglion cell survival in cats with optic nerve damage. *Invest Ophthalmol Vis Sci.* 2001; 42:966–974. [PubMed: 11274073]
83. Loeliger MM, Briscoe T, Rees SM. BDNF increases survival of retinal dopaminergic neurons after prenatal compromise. *Invest Ophthalmol Vis Sci.* 2008; 49:1282–1289. [PubMed: 18326759]
84. Sood BG, Madan A, Saha S, et al. Perinatal systemic inflammatory response syndrome and retinopathy of prematurity. *Pediatr Res.* 2010; 67:394. [PubMed: 20032809]
85. Rao R, Mashburn CB, Mao J, Wadhwa N, Smith GM, Desai NS. Brain-derived neurotrophic factor (BDNF) in infants < 32 weeks gestational age: Correlation with antenatal factors and postnatal outcomes. *Pediatr Res.* 2009; 65:548. [PubMed: 19190539]
86. Hellgren G, Willett K, Engstrom E, et al. Proliferative retinopathy is associated with impaired increase in BDNF and RANTES expression levels after preterm birth. *Neonatology.* 2010; 98:409–418. [PubMed: 21063127]
87. Hartnett ME, Morrison MA, Smith S, et al. Genetic Variants Associated With Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants. *Gene Variants in ROP in Extremely Low Birth Weight Infants.* *Invest Ophthalmol Vis Sci.* 2014; 55:6194–6203. [PubMed: 25118269]
88. Moravski CJ, Kelly DJ, Cooper ME, et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. *Hypertension.* 2000; 36:1099–1104. [PubMed: 11116132]
89. Liang S, Pan M, Hu N, et al. Association of angiotensin-converting enzyme gene 2350 G/A polymorphism with diabetic retinopathy in Chinese Han population. *Mol Biol Rep.* 2013; 40:463–468. [PubMed: 23065222]
90. Haider M, Devarajan L, Al-Essa M, Kumar H. Angiotensin-converting enzyme gene insertion/deletion polymorphism in Kuwaiti children with retinopathy of prematurity. *Neonatology.* 2002; 82:84–88.
91. Mohamed S, Schaa K, Cooper ME, et al. Genetic contributions to the development of retinopathy of prematurity. *Pediatr Res.* 2009; 65:193–197. [PubMed: 18787502]

92. Holash J, Wiegand S, Yancopoulos G. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. *Oncogene*. 1999; 18
93. Lee J, Kim KE, Choi D-K, et al. Angiopoietin-1 Guides Directional Angiogenesis Through Integrin  $\alpha$  v  $\beta$  5 Signaling for Recovery of Ischemic Retinopathy. *Sci Transl Med*. 2013; 5:203ra127–203ra127.
94. Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. *Prog Retin Eye Res*. 2015; 49:67–81. [PubMed: 26113211]
95. Feng Y, Hagen Fv, Pfister F, et al. Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. *Thromb Haemost*. 2007; 97:99. [PubMed: 17200776]
96. Sato T, Shima C, Kusaka S. Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity. *Am J Ophthalmol*. 2011; 151:353–357.e351. [PubMed: 21168819]
97. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. *N Engl J Med*. 2005; 353:782–792. [PubMed: 16120858]
98. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. *The Journal of clinical investigation*. 2008; 118:526–533. [PubMed: 18219389]
99. Yang Z, Wang H, Jiang Y, Hartnett ME. VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis. *The American journal of pathology*. 2014; 184:1230–1239. [PubMed: 24630601]
100. Yang N, Zhang W, He T, Xing Y. Exogenous erythropoietin aggravates retinal neovascularization in a murine model of proliferative retinopathy. *Turkish journal of medical sciences*. 2017; 47:1642–1650. [PubMed: 29152948]
101. Semenza GL. Oxygen sensing, homeostasis, and disease. *N Engl J Med*. 2011; 365:537–547. [PubMed: 21830968]
102. Lin M, Chen Y, Jin J, et al. Ischaemia-induced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal Müller cells. *Diabetologia*. 2011; 54:1554–1566. [PubMed: 21360191]
103. Hoppe G, Yoon S, Gopalan B, et al. Comparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity. *Proceedings of the National Academy of Sciences*. 2016; 113:E2516–E2525.
104. Morita M, Ohneda O, Yamashita T, et al. HLF/HIF 2 $\alpha$  is a key factor in retinopathy of prematurity in association with erythropoietin. *The EMBO Journal*. 2003; 22:1134–1146. [PubMed: 12606578]
105. Huang B, Deora AB, He K-L, et al. Hypoxia-inducible factor-1 drives annexin A2 system-mediated perivascular fibrin clearance in oxygen-induced retinopathy in mice. *Blood*. 2011; 118:2918–2929. [PubMed: 21788340]
106. Rankin EB, Biju MP, Liu Q, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. *J Clin Invest*. 2007; 117:1068. [PubMed: 17404621]
107. Wolfsberg TG, Primakoff P, Myles DG, White J. ADAM, a novel family of membrane proteins containing a Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. *The Journal of cell biology*. 1995; 131:275–278. [PubMed: 7593158]
108. Weskamp G, Mendelson K, Swendeman S, et al. Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. *Circ Res*. 2010; 106:932–940. [PubMed: 20110534]
109. Guaiquil VH, Hewing NJ, Chiang MF, Rosenblatt MI, Chan RP, Blobel CP. A Murine Model for Retinopathy of Prematurity Identifies Endothelial Cell Proliferation as a Potential Mechanism for Plus Disease Increased Proliferation of Vascular Cells in Plus Disease. *Invest Ophthalmol Vis Sci*. 2013; 54:5294–5302. [PubMed: 23833070]
110. Mahmoodi M, Sahebjam S, Smookler D, Khokha R, Mort JS. Lack of tissue inhibitor of metalloproteinases-3 results in an enhanced inflammatory response in antigen-induced arthritis. *The American journal of pathology*. 2005; 166:1733–1740. [PubMed: 15920158]
111. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. *Nature*. 2009; 461:747–753. [PubMed: 19812666]
112. Darlow BA, Lui K, Kusuda S, et al. International variations and trends in the treatment for retinopathy of prematurity. *Br J Ophthalmol*. 2017 bjophthalmol-2016-310041.

113. Mora JS, Waite C, Gilbert CE, Breidenstein B, Sloper JJ. A worldwide survey of retinopathy of prematurity screening. *Br J Ophthalmol*. 2017 bjophthalmol-2017-310709.
114. Moleta C, Campbell JP, Kalpathy-Cramer J, et al. Plus Disease in Retinopathy of Prematurity: Diagnostic Trends in 2016 Versus 2007. *Am J Ophthalmol*. 2017; 176:70–76. [PubMed: 28087400]
115. Manja V, Lakshminrusimha S, Cook DJ. Oxygen saturation target range for extremely preterm infants: a systematic review and meta-analysis. *JAMA pediatrics*. 2015; 169:332–340. [PubMed: 25664703]
116. Meng Q, Huang L, Sun Y, et al. Effect of high-density lipoprotein metabolic pathway gene variations and risk factors on neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in China. *PLoS One*. 2015; 10:e0143924. [PubMed: 26624898]
117. Helgason H, Sulem P, Duvvari MR, et al. A rare nonsynonymous sequence variant in C3 is associated with high risk of age-related macular degeneration. *Nat Genet*. 2013; 45:1371–1374. [PubMed: 24036950]
118. AMD Gene Consortium. Seven new loci associated with age-related macular degeneration. *Nat Genet*. 2013; 45:433–439. [PubMed: 23455636]
119. Burdon KP, Fogarty RD, Shen W, et al. Genome-wide association study for sight-threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene. *Diabetologia*. 2015; 58:2288–2297. [PubMed: 26188370]
120. Sheu WH-H, Kuo JZ, Lee I-T, et al. Genome-wide association study in a Chinese population with diabetic retinopathy. *Hum Mol Genet*. 2013; 22:3165–3173. [PubMed: 23562823]
121. Khor CC, Do T, Jia H, et al. Genome-wide association study identifies five new susceptibility loci for primary angle closure glaucoma. *Nat Genet*. 2016; 48:556–562. [PubMed: 27064256]
122. Bailey JNC, Loomis SJ, Kang JH, et al. Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open angle glaucoma. *Nat Genet*. 2016; 48:189. [PubMed: 26752265]
123. Vithana EN, Khor C-C, Qiao C, et al. Genome-wide association analyses identify three new susceptibility loci for primary angle closure glaucoma. *Nat Genet*. 2012; 44:1142–1146. [PubMed: 22922875]
124. Verhoeven VJ, Hysi PG, Wojciechowski R, et al. Genome-wide meta-analyses of multiethnicity cohorts identify multiple new susceptibility loci for refractive error and myopia. *Nat Genet*. 2013; 45:314–318. [PubMed: 23396134]
125. Solouki AM, Verhoeven VJ, Van Duijn CM, et al. A genome-wide association study identifies a susceptibility locus for refractive errors and myopia at 15q14. *Nat Genet*. 2010; 42:897. [PubMed: 20835239]
126. Hysi PG, Young TL, Mackey DA, et al. A genome-wide association study for myopia and refractive error identifies a susceptibility locus at 15q25. *Nat Genet*. 2010; 42:902–905. [PubMed: 20835236]
127. Syreeni A, El-Osta A, Forsblom C, et al. Genetic examination of SETD7 and SUV39H1/H2 methyltransferases and the risk of diabetes complications in patients with type 1 diabetes. *Diabetes*. 2011; 60:3073–3080. [PubMed: 21896933]
128. Zhong Q, Kowluru RA. Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. *Diabetes*. 2011; 60:1304–1313. [PubMed: 21357467]
129. McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. *Diabetes*. 2011; 60:1314–1323. [PubMed: 21357793]
130. Kowluru RA, Santos JM, Mishra M. Epigenetic modifications and diabetic retinopathy. *BioMed research international*. 2013; 2013
131. Zhong Q, Kowluru RA. Regulation of matrix metalloproteinase-9 by epigenetic modifications and the development of diabetic retinopathy. *Diabetes*. 2013; 62:2559–2568. [PubMed: 23423566]
132. Psaty BM, O'donnell CJ, Gudnason V, et al. Cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. *Circ Cardiovasc Genet*. 2009; 2:73–80. [PubMed: 20031568]

133. Lu Y, Vitart V, Burdon KP, et al. Genome-wide association analyses identify multiple loci associated with central corneal thickness and keratoconus. *Nat Genet.* 2013; 45:155–163. [PubMed: 23291589]
134. Jensen RA, Sim X, Smith AV, et al. Novel genetic loci associated with retinal microvascular diameter. *Circ Cardiovasc Genet.* 2015 CIRCGENETICS. 115.001142.
135. National Institute of Environmental Health Sciences. Genes Associated With Bronchopulmonary Dysplasia and Retinopathy of Prematurity. Available from: <https://clinicaltrials.gov/ct2/show/NCT01780155>. NLM identifier: NCT01780155. Accessed 05.10.17
136. Imaging and Informatics in ROP Research Consortium. Imaging and Informatics in Retinopathy of Prematurity. 2017. <http://i-rop.github.io/>. 2017 Accessed 10.10.17
137. Vannay Á, Dunai G, Bányász I, et al. Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity. *Pediatr Res.* 2005; 57:396–398. [PubMed: 15635051]
138. Kaya M, Çokaklı M, Berk AT, et al. Associations of VEGF/VEGF-Receptor and HGF/c-Met promoter polymorphisms with progression/regression of retinopathy of prematurity. *Curr Eye Res.* 2013; 38:137–142. [PubMed: 23094709]
139. Shastry BS, Qu X. Lack of association of the VEGF gene promoter (–634 G→ C and –460 C→ T) polymorphism and the risk of advanced retinopathy of prematurity. *Graefe's Archive for Clinical and Experimental Ophthalmology.* 2007; 245:741–743.
140. Kusuda T, Hikino S, Ohga S, et al. Genetic variation of vascular endothelial growth factor pathway does not correlate with the severity of retinopathy of prematurity. *J Perinatol.* 2011; 31:246–250. [PubMed: 20706192]
141. Kwinta P, Bik-Multanowski M, Mitkowska Z, Tomasik T, Pietrzyk JJ. The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity. *Graefe's Archive for Clinical and Experimental Ophthalmology.* 2008; 246:1467–1475.
142. Kalmeh ZA, Azarpira N, Mosallaei M, Hosseini H, Malekpour Z. Genetic polymorphisms of vascular endothelial growth factor and risk for retinopathy of prematurity in South of Iran. *Mol Biol Rep.* 2013; 40:4613–4618. [PubMed: 23644986]
143. Gismondi D, Ndoja L, Qu X, Shastry BS. Lack of association of VEGF gene 3'-UTR polymorphisms (C702T, C936T and G1612A) and the risk of developing advanced retinopathy of prematurity (ROP). *Graefe's Archive for Clinical and Experimental Ophthalmology.* 2012:1–3.
144. Shastry BS. Lack of association of VEGF (–2578 C→ A) and ANG 2 (–35 G→ C) gene polymorphisms with the progression of retinopathy of prematurity. *Graefe's Archive for Clinical and Experimental Ophthalmology.* 2009; 247:859–860.
145. Bányász I, Bokodi G, Vannay Á, et al. Genetic polymorphisms of vascular endothelial growth factor and angiopoietin 2 in retinopathy of prematurity. *Curr Eye Res.* 2006; 31:685–690. [PubMed: 16877277]
146. Hartnett ME, Cotten CM. Genomics in the neonatal nursery: Focus on ROP. Paper presented at: *Semin Perinatol.* 2015
147. Hiraoka M, Takahashi H, Orimo H, Hiraoka M, Ogata T, Azuma N. Genetic screening of Wnt signaling factors in advanced retinopathy of prematurity. *Mol Vis.* 2010; 16:2572–7. [PubMed: 21151595]
148. Rusai K, Vannay A, Szebeni B, et al. Endothelial nitric oxide synthase gene T-786C and 27-bp repeat gene polymorphisms in retinopathy of prematurity. *Mol Vis.* 2008; 14:286–290. [PubMed: 18334945]
149. Yanamandra K, Napper D, Pramanik A, Bocchini JA Jr, Dhanireddy R. Endothelial nitric oxide synthase genotypes in the etiology of retinopathy of prematurity in premature infants. *Ophthalmic Genet.* 2010; 31:173–177. [PubMed: 20809776]
150. Shastry BS. Endothelial nitric oxide synthase gene promoter polymorphism (T-786C) may be associated with advanced retinopathy of prematurity. *Graefe's Archive for Clinical and Experimental Ophthalmology.* 2013; 251:2251.

151. Hutcheson KA, Paluru PC, Bernstein SL, et al. Norrie disease gene sequence variants in an ethnically diverse population with retinopathy of prematurity. *Mol Vis.* 2005; 11:501–508. [PubMed: 16052165]
152. Dickinson JL, Sale MM, Passmore A, et al. Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity. *Clin Experiment Ophthalmol.* 2006; 34:682–688. [PubMed: 16970763]



Table 1

## Studies Investigating the Association Between VEGFA Genes and Retinopathy of Prematurity (ROP)

| Polymorphism                    | Study country  | Subjects  | Results  | Reference |
|---------------------------------|--|---|--|-----------|
| rs2010963<br>(-634G>C, +405G>C) | United Kingdom   | 91 treatment-requiring ROP (BW 779g [440–1185g], GA 25 wk [23–32 wk]), 97 non-treatment-requiring preterm infants (BW 920 g [448–2302g], GA 26 wk $\pm$ 2.9 wk)                                       | Higher frequency G allele among infants with threshold ROP         | 41        |
|                                 | Hungary  | 115 treatment-requiring ROP (BW 1160g $\pm$ 270g, GA 28.5 wk $\pm$ 2.0 wk), 86 mild or no ROP (BW 1200g $\pm$ 270g, GA 29.2 wk $\pm$ 2.9 wk)  | Higher frequency C allele among treated infants                    | 137       |
|                                 | Turkey   | 42 treatment-requiring ROP (BW 1097.5g $\pm$ 264.3g, GA 28.2 wk $\pm$ 2.4 wk), 50 regressed ROP (BW 1253.0g $\pm$ 212.2g, GA 29.7 wk $\pm$ 2.0 wk), 31 no ROP (BW 1345.6g $\pm$ 225.9g)               | No significant association   | 138       |
|                                 | United States  | 61 stage 4/5 ROP (BW 882g [600–1300g], GA 26 wk [23–30 wk]), 61 normal controls (BW 2430–3960g, GA 34–40 wk)  | No significant association   | 139       |
|                                 | Japan  | 127 ROP (944g [3778–2168g], GA 27 wk [22–33 wk]), 77 no ROP (BW 1596g [692–2400g], GA 32 wk [22–33 wk])   | No significant association   | 140       |
|                                 | Egypt  | 62 ROP (BW 1400g [1000–2110g], GA 32 wk [28–34 wk]), 40 no ROP (BW 1640g [1009–2800g], GA 33 wk [29–35 wk])   | High frequency of G allele in ROP                                  | 42        |
|                                 | Poland   | 60 treatment-requiring ROP (BW 900g $\pm$ 225g, GA 26.7 wk $\pm$ 2.3 wk), 20 regressed ROP (BW 1029g $\pm$ 231g, GA 27.5 wk $\pm$ 1.6 wk), 101 no ROP (BW 1153g $\pm$ 225g, GA 29.2 wk $\pm$ 2.05 wk) | No significant association   | 141       |
| Iran                            | 15 treatment-requiring ROP (BW 879g $\pm$ 81g, GA 27 wk $\pm$ 13 wk), 30 regressed ROP (BW 884g $\pm$ 63g, GA 27 wk $\pm$ 12 wk), 66 no ROP (BW 980g $\pm$ 81 g, GA 27 wk $\pm$ 10 wk) | No significant association  | 142  |           |
| rs1547651                       | Caucasian  | 43 ROP, 299 no ROP (all subjects GA 28 weeks)   | No significant association   | 43        |
| rs3025039<br>(+936C>T)          | Caucasian  | 43 ROP, 299 no ROP (all subjects GA 28 weeks)   | No significant association   | 43        |
|                                 | Iran   | 15 treatment-requiring ROP (BW 879g $\pm$ 81g, GA 27 wk $\pm$ 13 wk), 30 regressed ROP (BW 884g $\pm$ 63g, GA 27 wk $\pm$ 12 wk), 66 no ROP (BW 980g $\pm$ 81 g, GA 27 wk $\pm$ 10 wk)                | No significant association   | 142       |
|                                 | United States  | 33 stage 4/5 ROP, 49 normal controls  | No significant association   | 143       |
|                                 | Egypt  | 62 ROP (BW 1400g [1000–2110g], GA 32 wk [28–34 wk]), 40 no ROP (BW 1640g [1009–2800g], GA 33 wk [29–35 wk])   | No significant association   | 42        |
| rs833058                        | Italy  | 43 ROP, 299 no ROP (all subjects GA 28 weeks)   | No significant association   | 43        |
| rs833061<br>(-460C>T)           | Italy  | 43 ROP, 299 no ROP (all subjects GA 28 weeks)   | No significant association   | 43        |
|                                 | Hungary  | 115 treatment-requiring ROP (BW 1160g $\pm$ 270g, GA 28.5 wk $\pm$ 2.0 wk), 86 mild or no ROP (BW 1200g $\pm$ 270g, GA 29.2 wk $\pm$ 2.9 wk)  | High frequency of 460TT/405CC haplotype in treatment-requiring ROP | 137       |
|                                 | Turkey   | 42 treatment-requiring ROP (BW 1097.5g $\pm$ 270g, GA 28.2 wk $\pm$ 2.4 wk), 50 regressed ROP (BW 1253.0g $\pm$ 212.2g, GA 29.7 wk $\pm$ 2.0 wk), 31 no ROP (BW 1345.6g $\pm$ 225.9g)                 | No significant association   | 138       |



| Polymorphism | Study country | Subjects  | Results  | Reference |
|--------------|---------------|---|--|-----------|
|              | United States | 61 stage 4/5 ROP (BW 882g [600–1300g], GA 26 wk [23–30 wk]), 61 normal controls (BW 2430–3960g, GA 34–40 wk)  | No significant association   | 139       |
| +13553C>T    | Japanese      | 127 ROP (BW 944g [378–2168g], GA 27 wk [22–33 wk]), 77 no ROP (BW 1596g [692–2400g], GA 32 wk [22–33 wk])   | A significant association between the TT genotype and non-severe ROP for gestational age | 140       |
| +702C>T      | United States | 33 stage 4/5 ROP, 49 normal controls  | No significant association   | 143       |
| +1612G>A     | United States | 33 stage 4/5 ROP, 49 normal controls  | No significant association   | 143       |
| –2578C>A     | United States | ROP (BW 2430–3960g, GA 34–40 wk), no ROP (BW 600–1300g, GA 23–30 wk) (number of patients not reported)  | No significant association   | 144       |
|              | Hungary       | 90 treatment-requiring ROP (BW 1160g $\pm$ 300g, GA 28.5 wk $\pm$ 2.4 wk), 110 mild (stage 1 or 2) or no ROP (BW 1200g $\pm$ 280g, GA 28.5 wk $\pm$ 2.4 wk) | No significant association   | 145       |

Table lists investigated polymorphism and presence of statistical significance. Where noted in the original study, information is provided in parentheses regarding the birth weight (BW) and gestational age (GA) of patients. Brackets denote range of patient values and  $\pm$  denotes one standard deviation of range of each variable.

**Table 2**  
Summary of candidate gene studies of retinopathy of prematurity other than *VEGFA*

| Gene          | Variant   | Study country | Subjects  | Results   | Reference |
|---------------|---|---------------|---|---|-----------|
| <i>ACE</i>    | rs1799752   | Italy         | 299 ROP, 43 no ROP  | No significant association  | 43        |
|               | rs4291  |               |   |   |           |
| <i>AGT</i>    | 287-bp insertion in intron 16                               | Kuwait        | 74 ROP (53 regressed, 21 stage 4/5 ROP), 107 no ROP             | The incidence of the II genotype was higher in ROP cases, while the incidence of the DD genotype was significantly higher in advanced stage ROP cases compared to spontaneously regressing ROP cases. (I, insertion, D, deletion) | 90        |
|               |   | Italy         | 43 ROP, 299 no ROP  | No significant association  | 43        |
| <i>AGTR1</i>  | rs5186  | Italy         | 43 ROP, 299 no ROP  | No significant association  | 43        |
|               |   | United States | 102 ROP, 228 no ROP   | Significant association with ROP at $p < 0.01$ level of significance  | 91        |
| <i>ANGPT2</i> | -35G>C  | United States | Not specified   | No significant association  | 144       |
|               |   | Hungary       | 90 treatment-requiring ROP, 110 no or mild (stage 1 or 2) ROP   | No significant association  | 145       |
| <i>BDNF</i>   | rs7934165<br>rs2049046                                      | United States | 126 treatment-requiring ROP, 467 stage 1/2 ROP                  | Two intronic SNPs found to be associated with difference between mild and threshold ROP   | 146       |
|               |   | United States | 140 treatment-requiring ROP, 1257 no or mild (stage 1 or 2) ROP | Meta-analysis of two studies provided evidence of association of variant with severe ROP  | 146       |
| <i>CETP</i>   | rs289747  | United States | 102 ROP, 228 no ROP   | Significant association with ROP at $p < 0.01$ level  | 91        |
| <i>CFH</i>    | rs52985<br>rs800292   | United States | 102 ROP, 228 no ROP   | Increased protection against ROP as number of T alleles increased ( $p = 0.01$ )  | 91        |
|               |   | United States | 102 ROP, 228 no ROP   | Increased protection against ROP as number of T alleles increased ( $p = 0.01$ )  | 91        |
| <i>EPAS1</i>  | rs1867785   | United States | 102 ROP, 228 no ROP   | Significantly higher incidence of A allele in ROP   | 91        |
| <i>GPIBA</i>  | rs2243093   | United States | 102 ROP, 228 no ROP   | Significant association with ROP at $p < 0.01$ level  | 91        |
| <i>LRP5</i>   | rs143924910 (c.3656G>A), c.4148A>C, rs141407040 (c.4619C>T) | Japan         | 53 advanced ROP   | Direct sequencing of coding regions of LRP5 revealed 3 nonsynonymous DNA variants in 3 patients.  | 56        |
|               |   | Japan         | 17 advanced ROP, 51 no ROP                                      | Single patient with advanced ROP shown to have 3 bp insertion in exon 1 CTG repeat area not observed in 28 unaffected patients.   | 147       |

| Gene  | Variant   | Study country                                     | Subjects  | Results  | Reference |
|-------|---|---|---|--|-----------|
| NOS3  | rs2070744<br>(-786T>C)  | Italy   | 43 ROP, 299 no ROP  | No significant association   | 43        |
|       |   | Hungary   | 105 treatment-requiring ROP, 127 stage 1 or 2 ROP                                 | No significant association   | 148       |
|       | United States   | 15 ROP, 131 no ROP                                | significantly higher frequency of C allele in ROP                                 | 149  |           |
|       | United States   | 19 stage 4/5 ROP, 34 normal                       | significantly higher frequency of C allele in ROP                                 | 150  |           |
|       | United States   | 14 stage 4/5 ROP, 32 normal                       | No significant association  | 150  |           |
|       | United States   | 15 ROP, 131 no ROP                                | significantly higher frequency of T allele in ROP                                 | 149  |           |
|       | Italy   | 43 ROP, 299 no ROP                                | No significant association  | 43   |           |
|       | United States   | 15 stage 4/5, 32 normal controls                  | No significant association  | 150  |           |
|       | Hungary   | 105 treatment-requiring ROP, 127 stage 1 or 2 ROP | The aa genotype presented an independent risk factor for ROP requiring treatment. | 148  |           |
|       | Italy   | rs61722009  | 43 ROP, 299 no ROP  | No significant association   | 43        |
| FLT1  | c.+6724(TG) 13-23 dinucleotide repeat                               | Japan   | 127 ROP, 77 no ROP  | No significant association   | 140       |
| FZD4  | c.97 C>T; c.502 C>T<br>(double missense mutation)                   | United States                                     | 93 ROP, 98 normal controls  | Seven of 93 (7.5%) patients with ROP showed c.97 C>T; c.502 C>T double missense mutation.                            | 57        |
|       | rs80358282<br>(c.205C>T),<br>rs184709254<br>(c.380G>A),<br>c.631T>C | Japan   | 53 advanced ROP   | Direct sequencing of coding regions of FZD4 revealed 3 nonsynonymous DNA variants in 4 patients.                     | 56        |
|       | c.766A>G  | Unspecified                                       | 10 sporadic FEVR cases<br>20 advanced ROP cases                                   | PCR amplification of a large DNA fragment revealed one severe ROP case with c.766A>G. Significance not investigated. | 54        |
| HMOX1 | c.1109C>G,<br>c.609G>T  | Canada  | 71 severe ROP, 33 mild or no ROP  | Direct sequencing of coding regions of FZD4 revealed 2 nonsynonymous DNA variants in 2 patients.                     | 55        |
|       | rs3074372   | Italy   | 43 ROP, 299 no ROP  | No significant association   | 43        |
| IGF1R | c.3174G>A   | United States                                     | 52 stage 4/5 ROP, 33 normal controls  | No significant association   | 71        |
|       |   | Hungary   | 108 treatment-requiring ROP, 120 stage 1 or 2 ROP, 164 normal controls            | No significant association   | 70        |
| IHH   | rs3099  | United States                                     | 102 ROP, 228 no ROP   | Significant association with ROP at p < 0.01 level   | 91        |
| IL10  | -1082G>A  | Germany   | 31 stage 1 or 2 ROP, 13 stage 3 ROP, 29 no ROP                                    | No significant association   | 76        |
| IL1B  | +3953C>T  | Germany   | 31 stage 1 or 2 ROP, 13 stage 3 ROP, 29 no ROP                                    | No significant association   | 76        |

| Gene           | Variant  | Study country  | Subjects  | Results  | Reference |
|----------------|--|----------------|---|--|-----------|
| <i>KDR</i>     | 32G>A  | Turkey         | 42 treatment-requiring ROP, 50 regressed ROP, 31 normal controls        | No significant association   | 138       |
|                | g.+4422(AC)11-14 dinucleotide repeat                         | Japan          | 127 ROP, 77 no ROP  | No significant association   | 140       |
| <i>NDP</i>     | Sequencing of all 3 exons and UTRs                           | United States  | 54 severe ROP, 36 mild or no ROP, 22 normal controls, 31 normal parents | Six of 54 (11 %) infants with severe ROP had polymorphisms in the NDP.   | 151       |
|                | Direct sequencing of coding regions and noncoding exon 1     | Japan          | 53 advanced ROP   | No meaningful sequence changes   | 56        |
|                | 237A>G   | Japan          | 17 advanced ROP, 51 no ROP  | Single patient with AP-ROP found to have heterozygous substitution not observed in 51 unaffected cases   | 147       |
|                | 14 bp deletion in exon 1                                     | Australia      | 31 ROP (Stage 2 or greater), 90 no ROP                                  | Two twins with stage 3 regressed ROP and one unrelated patient with regressed stage 2 ROP displayed 14 bp deletion in CT repeat region. Also observed in a control patient. No statistical analysis. | 152       |
|                | 5 bp deletion in exon 1<br>26C>G<br>71 bp deletion in exon 1 | UK             | 31 ROP stage 3 or more, 16 regressed ROP, 2 no ROP                      | One patient had 5 bp deletion and C>G transversion at +26, one patient had 71 bp deletion in same exon 1 region. No statistical analysis.  | 61        |
|                | 12 bp insertion in exon 1<br>14 bp deletion in exon 1        | Japan          | 100 advanced ROP (stage 4/5), 6 regressed stage 3 ROP, 130 no ROP       | Two advanced ROP patients found to have disruptions in exon 1 of ND gene. No statistical analysis.   | 59        |
|                | 597C>A<br>110C>G   | Kuwait         | 95 ROP, 115 no ROP  | Significant association was found between ROP and 597C>A polymorphism. No significance found between 110C>G polymorphism and ROP.  | 60        |
|                | 121C>T<br>R121W<br>L108P                                     | United States  | 16 ROP, 50 normal controls  | One patient with a heterozygous base substitution, one pair of twins with novel R121W mutation, and one pair of twins with L108P missense mutation observed. No statistical analysis.                | 58        |
| <i>TBX5</i>    | rs1895602  | United States  | 102 ROP, 228 no ROP   | Significant association with ROP at $p < 0.01$ level   | 91        |
| <i>TGFB1</i>   | -509C>T  | United Kingdom | 91 treatment-requiring ROP, 97 stage 1/2 or no ROP                      | No significant association   | 41        |
| <i>TLR4</i>    | rs4986790<br>(c.896A>G)                                      | Germany        | 31 stage 1 or 2 ROP, 13 stage 3 ROP, 29 no ROP                          | No significant association   | 76        |
|                | -308G>A  | United Kingdom | 91 treatment-requiring ROP and 97 stage 1/2 or no ROP                   | No significant association   | 41        |
| <i>TNF</i>     |  | Germany        | 31 stage 1 or 2 ROP, 13 stage 3 ROP, 29 no ROP                          | No significant association   | 76        |
| <i>TSPAN12</i> | Direct sequencing of coding regions of <i>TSPAN12</i>        | Japan          | 53 advanced ROP   | No meaningful sequence changes   | 56        |